Trial Profile

An open label, multicenter study assessing efficacy of radiation therapy with atezolizumab for invasive bladder cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary)
Indications Bladder cancer
Focus Therapeutic Use

Most Recent Events

01 May 2025 Results identifying potential tissue biomarkers for achieving cCR using bladder preservation therapy in combination with atezolizumab and radiation therapy were published in the International Journal of Radiation Oncology, Biology, Physics
12 Oct 2023 Interim results of pCR and safety, published in the International Journal of Radiation Oncology, Biology, Physics
03 Nov 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com